Opus Genetics (IRD) Competitors $0.98 -0.01 (-0.87%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsTrends IRD vs. IVA, LPTX, VERU, RGLS, DERM, ANRO, BHST, IMUX, SKYE, and MNOVShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Inventiva (IVA), Leap Therapeutics (LPTX), Veru (VERU), Regulus Therapeutics (RGLS), Journey Medical (DERM), Alto Neuroscience (ANRO), BioHarvest Sciences (BHST), Immunic (IMUX), Skye Bioscience (SKYE), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry. Opus Genetics vs. Inventiva Leap Therapeutics Veru Regulus Therapeutics Journey Medical Alto Neuroscience BioHarvest Sciences Immunic Skye Bioscience MediciNova Opus Genetics (NASDAQ:IRD) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Do insiders and institutionals have more ownership in IRD or IVA? 15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, IRD or IVA? Opus Genetics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Does the MarketBeat Community prefer IRD or IVA? Inventiva received 18 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 80.00% of users gave Inventiva an outperform vote. CompanyUnderperformOutperformOpus GeneticsOutperform Votes2100.00% Underperform VotesNo VotesInventivaOutperform Votes2080.00% Underperform Votes520.00% Which has stronger valuation and earnings, IRD or IVA? Opus Genetics has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$8.38M3.69-$9.99M-$1.09-0.90Inventiva$15.62M7.90-$119.51MN/AN/A Do analysts rate IRD or IVA? Opus Genetics presently has a consensus price target of $8.00, suggesting a potential upside of 717.58%. Inventiva has a consensus price target of $13.25, suggesting a potential upside of 463.83%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is IRD or IVA more profitable? Inventiva has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Inventiva's return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-324.45% -63.65% -56.94% Inventiva N/A N/A N/A Does the media prefer IRD or IVA? In the previous week, Opus Genetics had 3 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Opus Genetics and 3 mentions for Inventiva. Opus Genetics' average media sentiment score of 0.70 beat Inventiva's score of 0.36 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInventiva beats Opus Genetics on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.89M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.9010.5990.0517.18Price / Sales3.69195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.445.094.784.78Net Income-$9.99M$151.83M$120.31M$225.60M7 Day Performance-4.07%-2.13%-1.92%-1.23%1 Month Performance-0.57%-3.10%11.50%3.36%1 Year PerformanceN/A11.54%30.59%16.60% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.7234 of 5 stars$0.98-0.9%$8.00+717.6%N/A$30.89M$8.38M-0.90N/ANews CoverageGap UpHigh Trading VolumeIVAInventiva3.1171 of 5 stars$2.32-5.3%$13.25+471.1%-45.3%$121.75M$15.62M0.00100LPTXLeap Therapeutics1.2897 of 5 stars$3.04+3.1%$7.50+146.7%-1.0%$116.49M$1.50M-1.5340VERUVeru1.9737 of 5 stars$0.76+5.0%$4.00+427.0%-3.5%$111.11M$14.09M-1.51189Earnings ReportAnalyst ForecastRGLSRegulus Therapeutics2.7405 of 5 stars$1.64+3.8%$10.80+558.5%+20.5%$107.42MN/A-1.4830News CoveragePositive NewsDERMJourney Medical2.548 of 5 stars$4.99-2.0%$9.38+87.9%N/A$104.24M$79.18M-5.4190ANROAlto Neuroscience3.2643 of 5 stars$3.85+0.5%$20.00+419.5%N/A$103.83M$210,000.000.00N/AGap UpBHSTBioHarvest SciencesN/A$6.32+2.8%$14.00+121.5%N/A$103.81M$22.43M-4.92N/AAnalyst ForecastIMUXImmunic2.933 of 5 stars$1.15+1.3%$11.80+930.6%-20.6%$103.14MN/A-0.9270Positive NewsSKYESkye Bioscience2.1878 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownMNOVMediciNova2.1642 of 5 stars$2.09-0.5%$9.00+330.6%+43.7%$102.51M$1M-9.9510Analyst ForecastPositive News Related Companies and Tools Related Companies Inventiva Alternatives Leap Therapeutics Alternatives Veru Alternatives Regulus Therapeutics Alternatives Journey Medical Alternatives Alto Neuroscience Alternatives BioHarvest Sciences Alternatives Immunic Alternatives Skye Bioscience Alternatives MediciNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IRD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts